Third quarter 2024 reported and adjusted* operating income increased 26% and 29% compared to prior year
Third quarter 2024 reported and adjusted EPS were $2.83 and $3.05, an increase of 20% and 3...
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers
VANCOUVER, British ...